Apimeds Pharmaceuticals US, Inc. (APUS) stock
APUSNYSEPharmaceutical PreparationsFiscal year ends December 31
$2.23−0.04 (-1.76%)
Close on Nov 13, 2026Market cap $3.37MP/E –Yield –
Apimeds Pharmaceuticals US r&d expenses
Research and development expenses are spending on new products and technology.
Apimeds Pharmaceuticals US's R&D Expenses for the twelve months ending Jun 30, 2026 was $2.84M. For fiscal 2025 it was $1.63M, up 1556.7% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.63M | +1556.7% |
| FY2023 | Dec 31, 2023 | $98.54K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $959.74K | +47.2% |
| Q1 FY2026 | Mar 31, 2026 | $901.14K | – |
| Q4 FY2025 | Dec 31, 2025 | $361.10K | – |
| Q3 FY2025 | Sep 30, 2025 | $619.69K | – |
| Q2 FY2025 | Jun 30, 2025 | $651.78K | – |
See a number that looks wrong?